Recent advances in genomics and therapeutics in mantle cell lymphoma

• Published in: Cancer treatment reviews Vol. 122; p. 102651
• Main Authors: Lu, Tingxun, Zhang, Jie, McCracken, Jenna M, Young, Ken H
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2024
• Subjects: Adult; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Genomics; Humans; Lymphoma, Mantle-Cell - drug therapy; Lymphoma, Mantle-Cell - genetics; Prognosis; Resistance; Novel agents; Prognosis; BTK inhibitor; Mantle cell lymphoma
• ISSN: 0305-7372; 1532-1967
• DOI: 10.1016/j.ctrv.2023.102651

Over the past decades, significant strides have been made in understanding the pathobiology, prognosis, and treatment options for mantle cell lymphoma (MCL). The heterogeneity observed in MCL's biology, genomics, and clinical manifestations, including indolent and aggressive forms, is intricately linked to factors such as the mutational status of the variable region of the immunoglobulin heavy chain gene, epigenetic profiling, and Sox11 expression. Several intriguing subtypes of MCL, such as Cyclin D1-negative MCL, in situ mantle cell neoplasm, CCND1/IGH FISH-negative MCL, and the impact of karyotypic complexity on prognosis, have been explored. Notably, recent immunochemotherapy regimens have yielded long-lasting remissions in select patients. The therapeutic landscape for MCL is continuously evolving, with a shift towards nonchemotherapeutic agents like ibrutinib, acalabrutinib, and venetoclax. The introduction of BTK inhibitors has brought about a transformative change in MCL treatment. Nevertheless, the challenge of resistance to BTK inhibitors persists, prompting ongoing efforts to discover strategies for overcoming this resistance. These strategies encompass non-covalent BTK inhibitors, immunomodulatory agents, BCL2 inhibitors, and CAR-T cell therapy, either as standalone treatments or in combination regimens. Furthermore, developing novel drugs holds promise for further improving the survival of patients with relapsed or refractory MCL. In this comprehensive review, we methodically encapsulate MCL's clinical and pathological attributes and the factors influencing prognosis. We also undertake an in-depth examination of stratified treatment alternatives. We investigate conceivable resistance mechanisms in MCL from a genetic standpoint and offer precise insights into various therapeutic approaches for relapsed or refractory MCL.